<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is a long-term complication of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">pediatric cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively studied pediatric t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients treated at MD Anderson from 1975 to 2007 </plain></SENT>
<SENT sid="2" pm="."><plain>We also compared those patients to pediatric patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> during this time interval </plain></SENT>
<SENT sid="3" pm="."><plain>Among 2589 children with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treated at MD Anderson, we identified 22 patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> had a median age of 14 years </plain></SENT>
<SENT sid="5" pm="."><plain>There was a male and Hispanic predominance </plain></SENT>
<SENT sid="6" pm="."><plain>The most common primary <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> were <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> and Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The median latency period was 4.1 years </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients received supportive care only </plain></SENT>
<SENT sid="9" pm="."><plain>Group 1 (n=5) underwent stem cell transplantation without induction chemotherapy </plain></SENT>
<SENT sid="10" pm="."><plain>Group 2 (n=5) patients received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-type chemotherapy and a stem cell transplant postremission (n=5) </plain></SENT>
<SENT sid="11" pm="."><plain>Group 3 (n=4) received a stem cell transplant as salvage therapy </plain></SENT>
<SENT sid="12" pm="."><plain>The respective 2-year survival rates for groups 1, 2, and 3 were 20%, 40%, and 25% (P=0.85) </plain></SENT>
<SENT sid="13" pm="."><plain>Patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were younger (P=0.001) and higher rates of complete remission (P=0.03), and survival (P&lt;0.0001) </plain></SENT>
<SENT sid="14" pm="."><plain>Independent factors predicting shorter survival were poor/intermediate-risk cytogenetics (P=0.01), lower <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level (P=0.0001), and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (vs. de novo) (P=0.003) </plain></SENT>
<SENT sid="15" pm="."><plain>Childhood t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> has a poor prognosis </plain></SENT>
<SENT sid="16" pm="."><plain>Although patients benefited from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-type induction chemotherapy followed by stem cell transplantation as postremission therapy, effective therapies, and prevention are needed </plain></SENT>
</text></document>